To note, in recent years, Emicizumab, a bispecific monoclonal antibody that mimics the action of FVIII, approved for congenital hemophilia A with and without FVIII inhibitors, has emerged as a novel off-label therapeutic option for treating AHA [9,10]. Here, F8 is linked to autoimmune hemolytic anemia.